Screener
Halozyme Therapeutics HALO Accrued outsourced manufacturing expenses
Accrued outsourced manufacturing expenses at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept halo:AccruedOutsourcedManufacturingExpenses.
The source filing: Halozyme Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:11 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001159036-26-000104
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Accrued compensation and payroll taxes | $20,684 | $28,621 |
| Accrued outsourced manufacturing expenses | 5,181 | 11,775 |
| Taxes payable | 26,426 | 44,148 |
| Product returns and sales allowance | 44,108 | 46,594 |
| Other accrued expenses | 86,264 | 104,349 |
| Lease liability | 31,879 | 34,569 |
| Total accrued expenses | 214,542 | 270,056 |
| Less long-term portion | (102,681) | (113,863) |
Item 1. Financial Statements
FAQ
- What is Halozyme Therapeutics's accrued outsourced manufacturing expenses?
- Halozyme Therapeutics (HALO) reported accrued outsourced manufacturing expenses of $5.18M in Q2 2026.
- How has Halozyme Therapeutics's accrued outsourced manufacturing expenses changed year-over-year?
- Halozyme Therapeutics's accrued outsourced manufacturing expenses decreased by 48.0% year-over-year, from $9.96M to $5.18M.
- What is the long-term trend for Halozyme Therapeutics's accrued outsourced manufacturing expenses?
- Over 3 years (2022 to 2025), Halozyme Therapeutics's accrued outsourced manufacturing expenses has grown at a -1.1% compound annual growth rate (CAGR), from $12.19M to $11.78M.
- What does accrued outsourced manufacturing expenses mean?
- Accrued outsourced manufacturing expenses as reported by Halozyme Therapeutics, Inc..
Ask your AI about Halozyme Therapeutics's accrued outsourced manufacturing expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude